Skip to main content
Top
Published in: Pathology & Oncology Research 3/2020

01-07-2020 | Original Article

The Time Between Chemoradiation and Surgery for Rectal Carcinoma Negatively Influences Mesorectal Excision Quality

Authors: Igor Sirák, Denisa Pohanková, Alexander Ferko, Eva Hovorková, Tomáš Rozkoš, Milan Vošmik, Miroslav Hodek, Petr Paluska, David Buka, Jakub Grepl, Jiří Petera

Published in: Pathology & Oncology Research | Issue 3/2020

Login to get access

Abstract

Total mesorectal excision quality (TMEq) is a prognostic factor associated with local recurrence in rectal adenocarcinoma. Neoadjuvant chemoradiotherapy (NCRT) reduces the risk of tumor recurrence, but may compromise TMEq. The time between NCRT and surgery (TTS) and how it influences TMEq and tumor control were evaluated. In prospective registry, 236 patients after NCRT and TME were analyzed. NCRT involved radiotherapy with 45 Gy to the pelvis, plus tumor boost dose 5.4 Gy with concurrent 5-fluorouracil infusion. NCRT was followed by TME after 9 weeks on average (median 9.4 ± SD 2.5). TMEq was parametrically analyzed by standard three-grade system. With median follow-up of 47.5 months, 3-year overall survival (OS) was 83.8%, disease-free survival (DFS) was 77.7%, and 6.4% was the rate of local recurrence (LR). TTS was not associated with OS, DFS, or LR. TMEq was found to be associated with LR in univariate analysis, but not in multivariate, where pathological tumor stage and resection margins remained dominant predictors. TMEq was negatively influenced by inferior location of the tumor, longer TTS, higher tumor and nodal stage, presence of tumor perforation, perineural invasion, and close/positive resection margins. Nonetheless, TTS remained a strong predictor of TMEq in multivariate analyses. TTS was proven to be an independent predictor of TMEq. With longer TTS, fewer complete TME with intact mesorectal plane were observed. However, TTS was not associated with survival deterioration or tumor recurrence. These were negatively influenced by other factors interfering with TMEq, especially by pathological tumor stage and resection margins.
Literature
1.
go back to reference Parfitt JR, Driman DK (2007) The total mesorectal excision specimen for rectal cancer: a review of its pathological assessment. J Clin Pathol 60(8):849–855CrossRef Parfitt JR, Driman DK (2007) The total mesorectal excision specimen for rectal cancer: a review of its pathological assessment. J Clin Pathol 60(8):849–855CrossRef
2.
go back to reference Heald RJ, Ryall RD (1986) Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1(8496):1479–1482CrossRef Heald RJ, Ryall RD (1986) Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1(8496):1479–1482CrossRef
3.
go back to reference Kapiteijn E, Putter H, van de Velde CJ, Cooperative investigators of the Dutch ColoRectal Cancer Group (2002) Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in the Netherlands. Br J Surg 89(9):1142–1149CrossRef Kapiteijn E, Putter H, van de Velde CJ, Cooperative investigators of the Dutch ColoRectal Cancer Group (2002) Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in the Netherlands. Br J Surg 89(9):1142–1149CrossRef
4.
go back to reference van Gijn W, Marijnen CA, Nagtegaal ID et al (2011) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12(6):575–582CrossRef van Gijn W, Marijnen CA, Nagtegaal ID et al (2011) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12(6):575–582CrossRef
5.
go back to reference Bosset JF, Calais G, Mineur L et al (2014) Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 15(2):184–190CrossRef Bosset JF, Calais G, Mineur L et al (2014) Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 15(2):184–190CrossRef
6.
go back to reference Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731–1740CrossRef Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731–1740CrossRef
7.
go back to reference Sauer R, Liersch T, Merkel S et al (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30(16):1926–1933CrossRef Sauer R, Liersch T, Merkel S et al (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30(16):1926–1933CrossRef
8.
go back to reference Nagtegaal ID, van de Velde CJ, van der Worp E et al (2002) Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol 20(7):1729–1734CrossRef Nagtegaal ID, van de Velde CJ, van der Worp E et al (2002) Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol 20(7):1729–1734CrossRef
9.
go back to reference Leonard D, Penninckx F, Fieuws S et al (2010) PROCARE, a multidisciplinary Belgian project on Cancer of the rectum. Factors predicting the quality of total mesorectal excision for rectal cancer. Ann Surg 252(6):982–988CrossRef Leonard D, Penninckx F, Fieuws S et al (2010) PROCARE, a multidisciplinary Belgian project on Cancer of the rectum. Factors predicting the quality of total mesorectal excision for rectal cancer. Ann Surg 252(6):982–988CrossRef
10.
go back to reference Baik SH, Kim NK, Lee KY et al (2008) Factors influencing pathologic results after total mesorectal excision for rectal cancer: analysis of consecutive 100 cases. Ann Surg Oncol 15(3):721–728CrossRef Baik SH, Kim NK, Lee KY et al (2008) Factors influencing pathologic results after total mesorectal excision for rectal cancer: analysis of consecutive 100 cases. Ann Surg Oncol 15(3):721–728CrossRef
11.
go back to reference Deng H, Chen H, Zhao L et al (2015) Quality of laparoscopic total mesorectal excision: results from a single institution in China. Hepatogastroenterology 62(138):264–267PubMed Deng H, Chen H, Zhao L et al (2015) Quality of laparoscopic total mesorectal excision: results from a single institution in China. Hepatogastroenterology 62(138):264–267PubMed
12.
go back to reference Garlipp B, Ptok H, Schmidt U et al (2012) Factors influencing the quality of total mesorectal excision. Br J Surg 99(5):714–720CrossRef Garlipp B, Ptok H, Schmidt U et al (2012) Factors influencing the quality of total mesorectal excision. Br J Surg 99(5):714–720CrossRef
13.
go back to reference Bosch SL, Nagtegaal ID (2012) The importance of the Pathologist's role in assessment of the quality of the Mesorectum. Curr Colorectal Cancer Rep 8(2):90–98CrossRef Bosch SL, Nagtegaal ID (2012) The importance of the Pathologist's role in assessment of the quality of the Mesorectum. Curr Colorectal Cancer Rep 8(2):90–98CrossRef
14.
go back to reference Roh MS, Colangelo LH, O'Connell MJ et al (2009) Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27:5124–5130CrossRef Roh MS, Colangelo LH, O'Connell MJ et al (2009) Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27:5124–5130CrossRef
15.
go back to reference Sautter-Bihl ML, Hohenberger W, Fietkau R et al (2013) Rectal cancer: when is the local recurrence risk low enough to refrain from the aim to prevent it? Strahlenther Onkol 189(2):105–110CrossRef Sautter-Bihl ML, Hohenberger W, Fietkau R et al (2013) Rectal cancer: when is the local recurrence risk low enough to refrain from the aim to prevent it? Strahlenther Onkol 189(2):105–110CrossRef
16.
go back to reference Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93(10):1215–1223CrossRef Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93(10):1215–1223CrossRef
17.
go back to reference Hernando-Requejo O, López M, Cubillo A et al (2014) Complete pathological responses in locally advanced rectal cancer after preoperative IMRT and integrated-boost chemoradiation. Strahlenther Onkol 190(6):515–520CrossRef Hernando-Requejo O, López M, Cubillo A et al (2014) Complete pathological responses in locally advanced rectal cancer after preoperative IMRT and integrated-boost chemoradiation. Strahlenther Onkol 190(6):515–520CrossRef
18.
go back to reference Wong RK, Tandan V, De Silva S, Figueredo A (2007) Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev 18(2):CD002102 Wong RK, Tandan V, De Silva S, Figueredo A (2007) Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev 18(2):CD002102
19.
go back to reference Foster JD, Jones EL, Falk S et al (2013) Timing of surgery after long-course neoadjuvant chemoradiotherapy for rectal cancer: a systematic review of the literature. Dis Colon Rectum 56(7):921–930CrossRef Foster JD, Jones EL, Falk S et al (2013) Timing of surgery after long-course neoadjuvant chemoradiotherapy for rectal cancer: a systematic review of the literature. Dis Colon Rectum 56(7):921–930CrossRef
20.
go back to reference Sun Z, Adam MA, Kim J et al (2016) Optimal timing to surgery after neoadjuvant Chemoradiotherapy for locally advanced rectal Cancer. J Am Coll Surg 222(4):367–374CrossRef Sun Z, Adam MA, Kim J et al (2016) Optimal timing to surgery after neoadjuvant Chemoradiotherapy for locally advanced rectal Cancer. J Am Coll Surg 222(4):367–374CrossRef
21.
go back to reference Pellizzon ACA (2019) Pre-operative radiotherapy to improve local control and survival in rectal cancer optimal time intervals between radiation and surgery. Pract Rep Oncol Radiother 24(1):1–2CrossRef Pellizzon ACA (2019) Pre-operative radiotherapy to improve local control and survival in rectal cancer optimal time intervals between radiation and surgery. Pract Rep Oncol Radiother 24(1):1–2CrossRef
22.
go back to reference Petersen C (2013) Optimal timing of surgery for rectal cancer after neoadjuvant chemoradiotherapy: which patients would benefit from waiting? Strahlenther Onkol 189(10):904–906CrossRef Petersen C (2013) Optimal timing of surgery for rectal cancer after neoadjuvant chemoradiotherapy: which patients would benefit from waiting? Strahlenther Onkol 189(10):904–906CrossRef
23.
go back to reference Sloothaak DA, Geijsen DE, van Leersum NJ et al (2013) Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg 100(7):933–939CrossRef Sloothaak DA, Geijsen DE, van Leersum NJ et al (2013) Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg 100(7):933–939CrossRef
24.
go back to reference Lefevre JH, Mineur L, Kotti S et al (2016) Effect of interval (7 or 11 weeks) between neoadjuvant Radiochemotherapy and surgery on complete pathologic response in rectal Cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol 34(31):3773–3778CrossRef Lefevre JH, Mineur L, Kotti S et al (2016) Effect of interval (7 or 11 weeks) between neoadjuvant Radiochemotherapy and surgery on complete pathologic response in rectal Cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol 34(31):3773–3778CrossRef
25.
go back to reference Buka D, Dvorak J, Sitorova V et al (2017) The changes of tumour vascular endothelial growth factor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma. Contemp Oncol 21(1):48–53 Buka D, Dvorak J, Sitorova V et al (2017) The changes of tumour vascular endothelial growth factor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma. Contemp Oncol 21(1):48–53
26.
go back to reference Hodek M, Sirák I, Ferko A et al (2016) Neoadjuvant chemoradiotherapy of rectal carcinoma : baseline hematologic parameters influencing outcomes. Strahlenther Onkol 192(9):632–640CrossRef Hodek M, Sirák I, Ferko A et al (2016) Neoadjuvant chemoradiotherapy of rectal carcinoma : baseline hematologic parameters influencing outcomes. Strahlenther Onkol 192(9):632–640CrossRef
27.
go back to reference Dvorak J, Sitorova V, Ryska A et al (2012) Prognostic significance of changes of tumor epidermal growth factor receptor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma. Strahlenther Onkol 188(9):833–838CrossRef Dvorak J, Sitorova V, Ryska A et al (2012) Prognostic significance of changes of tumor epidermal growth factor receptor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma. Strahlenther Onkol 188(9):833–838CrossRef
Metadata
Title
The Time Between Chemoradiation and Surgery for Rectal Carcinoma Negatively Influences Mesorectal Excision Quality
Authors
Igor Sirák
Denisa Pohanková
Alexander Ferko
Eva Hovorková
Tomáš Rozkoš
Milan Vošmik
Miroslav Hodek
Petr Paluska
David Buka
Jakub Grepl
Jiří Petera
Publication date
01-07-2020
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-019-00742-w

Other articles of this Issue 3/2020

Pathology & Oncology Research 3/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine